Saturday - May 10, 2025
FARMINGTON, Utah / Oct 31, 2024 / Business Wire / PACS Group, Inc. (NYSE: PACS) (“PACS Group” or the “Company”), today announced that it will release its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Management will host a call on Thursday, November 7, 2024, at 5:00 p.m. Eastern Time to discuss the financial results and related information.
PACS Group invites current and prospective investors to listen to the call via webcast by going to the Investors section of the PACS Group website at https://ir.pacs.com/ or https://event.choruscall.com/mediaframe/webcast.html?webcastid=ngVWINHF or by dialing 877-407-0621 / +1 215-268-9899. A recording of the call will be available for replay via the website for 30 days following the call. The Company’s press releases, SEC filings, public conference calls, webcasts and website frequently disclose information that may be material to investors, and the Company encourages investors and others interested in the Company to regularly monitor those outlets for important Company information.
About PACS Group
PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. Founded in 2013, PACS Group is one of the largest post-acute platforms in the United States. Its independent subsidiaries operate over 276 post-acute care facilities across 15 states serving more than 30,000 patients daily.
Last Trade: | US$10.43 |
Daily Change: | -0.17 -1.60 |
Daily Volume: | 328,348 |
Market Cap: | US$1.620B |
November 06, 2024 November 01, 2024 September 10, 2024 September 09, 2024 September 03, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load